Tesofensine Interactions: Alcohol, Caffeine, Food & Other Compounds

What the Interaction Literature on Tesofensine Actually Covers

Tesofensine is an investigational triple monoamine reuptake inhibitor that was developed and studied as a candidate anti-obesity agent. Reviews of centrally acting obesity pharmacotherapy placed it within the class of monoamine-modulating compounds alongside earlier and later agents (PMID 30014268), and other reviews of emerging molecules against obesity discussed it among drug candidates that were in clinical development rather than in routine clinical use (PMID 24064009).

That development stage matters for interaction questions. Compounds that reach broad clinical use usually accumulate dedicated drug–drug and food-effect studies. In the verified literature summarised on this page, no controlled study examined tesofensine together with alcohol, and no controlled study examined tesofensine together with caffeine or other common stimulants. Where this page discusses those combinations, it describes the mechanistic reasoning researchers apply to monoamine reuptake inhibitors in general and labels that reasoning explicitly — it does not report interaction findings, because none exist in the cited set.

Two papers in the verified set do bear directly on co-administration. A rat study combined tesofensine with anti-hypertensive treatment and reported that appetite suppression was preserved while cardiovascular adverse effects were prevented (PMID 23784901). A clinical pharmacokinetics paper developed a quantitative enterohepatic circulation model and evaluated it using tesofensine and meloxicam data (PMID 19705923). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medicines, supplements or health conditions.

The Pharmacology That Frames Every Interaction Question

Interaction reasoning starts with mechanism. Structural work on triple reuptake inhibitors described the molecular basis for how this drug class engages monoamine transporters, providing a structural account of their pharmacotherapeutic action (PMID 41392177). Because a triple reuptake inhibitor acts at serotonin, noradrenaline and dopamine transport simultaneously, researchers expect its effects to intersect with any other agent, food state or behaviour that also shifts monoamine signalling.

Downstream pathways have been mapped in animal models. One study in diet-induced obese rats reported that tesofensine produced appetite suppression through indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways (PMID 20200509). Another study in diet-induced obese rats reported that tesofensine decreased food intake and body weight and decreased striatal dopamine D2/D3 receptor availability (PMID 21889317). More recent electrophysiological work reported that tesofensine silenced GABAergic hypothalamic neurons, linking the compound to inhibitory circuitry in a region central to feeding control (PMID 38656972).

Researchers treat these three findings as the mechanistic backbone for interaction hypotheses: adrenergic and dopaminergic signalling (PMID 20200509), striatal dopamine receptor changes (PMID 21889317) and hypothalamic circuit effects (PMID 38656972). None of those papers tested a second substance alongside tesofensine, so they describe mechanism, not interaction.

Alcohol: What the Verified Literature Contains

No study in the verified citation set administered alcohol with tesofensine, in humans or in animals. There is therefore no reported finding on how the combination affects appetite, blood pressure, sleep, subjective intoxication or pharmacokinetics.

Mechanistic reasoning only (not interaction evidence): researchers reason about alcohol and centrally acting anti-obesity drugs on two grounds. First, reviews of neuropsychiatric adverse effects of centrally acting anti-obesity drugs catalogued mood, sleep and central nervous system effects as a recurring theme for this drug class (PMID 21951371), and alcohol is itself a central nervous system depressant, which is why overlapping CNS effects are the usual starting hypothesis. Second, because tesofensine's described mechanism involves monoamine transporters (PMID 41392177) and dopaminergic reward circuitry (PMID 21889317), investigators have theoretical interest in whether monoamine reuptake inhibition alters alcohol-related reward signalling. That interest is a hypothesis about where to look, not a described result.

Caffeine and Other Stimulants: What the Verified Literature Contains

No verified study co-administered caffeine, ephedrine, other xanthines or amphetamine-type stimulants with tesofensine. No caffeine-specific pharmacokinetic or pharmacodynamic result for tesofensine appears in the cited papers.

Mechanistic reasoning only (not interaction evidence): the most frequently cited reason for interest here is cardiovascular. A rat study of tesofensine reported cardiovascular adverse effects that anti-hypertensive treatment prevented, while appetite suppression was maintained (PMID 23784901), and reviews of the safety of anti-obesity drugs discussed cardiovascular and central nervous system signals as core safety considerations for this category (PMID 25114779). Because caffeine has its own sympathomimetic and sleep-disrupting profile, researchers frame the combination as a question about additive cardiovascular and arousal effects. Again, that framing is reasoning by mechanism; the verified literature did not test it.

Food, Fasting and Absorption: What Studies Report

The most directly relevant verified paper here is pharmacokinetic rather than nutritional. A clinical pharmacokinetics paper developed a quantitative enterohepatic circulation model and evaluated it using data from tesofensine and meloxicam (PMID 19705923). Enterohepatic circulation describes a cycle in which a compound or its metabolites are secreted in bile, stored, released into the intestine and reabsorbed. Researchers use models of this kind to account for irregular plasma concentration–time profiles that a simple one-pass absorption model cannot reproduce; that modelling rationale is the standard mechanistic explanation for why bile-cycling compounds are studied with attention to gastrointestinal events.

What the verified set does not contain is a dedicated food-effect study of tesofensine — no fed-versus-fasted crossover, no high-fat-meal comparison, no result on whether meal timing shifted exposure. Statements about taking tesofensine with or without food therefore have no support in this citation set, and none is offered here.

Food matters to the tesofensine literature in a different way: as the outcome being measured rather than a variable being manipulated. Studies in diet-induced obese rats reported reduced food intake and body weight (PMID 21889317) and appetite suppression attributed to adrenergic and dopaminergic pathways (PMID 20200509), while hypothalamic recordings reported silencing of GABAergic neurons in a feeding-related region (PMID 38656972). In these designs, diet composition was part of the model used to create obesity, not an interaction being characterised.

Antihypertensive Co-Administration: The One Combination Study

The single co-administration experiment in the verified set is the rat study in which anti-hypertensive treatment was given with tesofensine. Researchers reported that the anti-hypertensive treatment preserved tesofensine's appetite suppression while preventing its cardiovascular adverse effects (PMID 23784901). Two features of that design are worth noting for anyone reading the literature: the work was conducted in rats, and the question asked was whether a pharmacological countermeasure could separate the weight-related effect from the cardiovascular effect. It was not a study of human dosing, and it did not establish a clinical co-treatment strategy.

Reviews of anti-obesity drug safety placed cardiovascular monitoring at the centre of how this class was evaluated (PMID 25114779), and reviews of future obesity pharmacotherapy discussed how such signals shaped the development path of candidate agents (PMID 29504049).

Serotonergic, Noradrenergic and Dopaminergic Compounds

Questions about combining tesofensine with antidepressants, monoamine oxidase inhibitors, other reuptake inhibitors or dopaminergic drugs are common. The verified literature contains no study administering any of those alongside tesofensine, so there is no reported outcome — not a favourable one and not an unfavourable one.

Mechanistic reasoning only (not interaction evidence): the structural account of triple reuptake inhibitor action describes engagement of monoamine transporters as the defining feature of the class (PMID 41392177). Pharmacologists reason that when two agents act on the same transporter systems, pharmacodynamic overlap is the expected question, and reviews of neuropsychiatric adverse effects of centrally acting anti-obesity drugs explain why the mood and CNS domain has historically been scrutinised for this category (PMID 21951371). Reviews of past, current and future obesity pharmacotherapy similarly described how mechanism-based expectations guided monitoring in this field (PMID 21197148).

Evidence Map by Combination

Adverse Events and Tolerability: What Studies Report

Interaction curiosity usually traces back to the adverse-event profile, so it is worth summarising what the verified reviews reported. A review of the safety of anti-obesity drugs examined the tolerability of agents developed for weight management, including centrally acting candidates (PMID 25114779). A separate review focused specifically on neuropsychiatric adverse effects of centrally acting anti-obesity drugs and discussed why psychiatric and CNS outcomes were tracked closely in this category (PMID 21951371).

On the cardiovascular side, the rat study reported that tesofensine produced cardiovascular adverse effects that anti-hypertensive treatment prevented (PMID 23784901). Reviews of emerging anti-obesity molecules and of future obesity pharmacotherapy discussed how such findings influenced the way candidate agents were positioned in development (PMID 24064009, PMID 29504049). None of these publications reported adverse events arising specifically from combining tesofensine with alcohol, caffeine or food.

How Researchers Read an Absence of Interaction Data

Absence of a study is not a statement that a combination is inert, and it is not a statement that it is hazardous. In pharmacology, an untested combination is simply uncharacterised. Investigators then fall back on three tools: known mechanism, in this case triple monoamine transporter engagement described structurally (PMID 41392177); known disposition, in this case the enterohepatic circulation modelling performed with tesofensine data (PMID 19705923); and class-level safety experience, summarised in anti-obesity drug safety and neuropsychiatric reviews (PMID 25114779, PMID 21951371). Each tool generates hypotheses that a real interaction study would have to confirm or refute.

Readers comparing sources should note where a claim comes from. A statement traceable to a co-administration experiment, such as the preserved appetite suppression alongside prevented cardiovascular effects in rats (PMID 23784901), rests on data. A statement about alcohol or caffeine with tesofensine, by contrast, rests on inference from mechanism, and the verified literature reviewed here offers no measurement to support or contradict it.

References

• Structural basis for pharmacotherapeutic action of triple reuptake inhibitors (Nature Communications, 2025)
• Safety of antiobesity drugs (Therapeutic Advances in Drug Safety, 2013)
• Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons (PLoS One, 2024)
• New and emerging drug molecules against obesity (Journal of Cardiovascular Pharmacology and Therapeutics, 2014)
• Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats (Obesity, 2013)
• A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam (Clinical Pharmacokinetics, 2009)
• Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats (European Neuropsychopharmacology, 2012)
• Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat (Neuropsychopharmacology, 2010)
• Pharmacotherapies for obesity: past, current, and future therapies (Journal of Obesity, 2011)
• Centrally Acting Agents for Obesity: Past, Present, and Future (Drugs, 2018)
• Neuropsychiatric adverse effects of centrally acting antiobesity drugs (CNS Neuroscience & Therapeutics, 2011)
• Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon (Current Obesity Reports, 2018)